Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Otsuka (Group)

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy, "Otsuka-people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases, and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. For more information, please visit www.otsuka.co.jp/en. About Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OPDC is well established in the scientific community as a globally-focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The company is dedicated to improving the quality of human life and patient health around the world with a strong commitment to research and development in the areas of neuroscience, cardiovascular diseases, and oncology. OPDC is part of the Otsuka Group companies. For more information, visit www.otsuka-us.com. OPDC is a subsidiary of Otsuka America, Inc., which is wholly owned by Otsuka Pharmaceutical Co., Ltd. *

 

Period Start 1964-08-10 established
Product Industry pharmaceutical
     
Region Region Japan_oo
  Country Japan
  City 101-0048 Tokyo
    Address record changed: 2013-07-11
     
Basic data Employees H: 10,001 to 50,00 (2007-03-31)
  Currency USD
  Annual sales 6,800,000,000 (sales (2005 fiscal))
     
    * Document for �About Section�: H. Lundbeck A/S. (11/22/11). "Press Release: NDA for Aripiprazole Depot Formulation for Maintenance Treatment of Adult Patients with Schizophrenia Accepted by the FDA".
     
   
Record changed: 2019-07-06

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Otsuka (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top